课题基金 / 基金详情

The role of dietary cholesterol in Nonalcoholic fatty liver disease through the action of gut microbiota

The role of dietary cholesterol in Nonalcoholic fatty liver disease through the action of gut microbiota
膳食胆固醇通过肠道微生物群的作用在非酒精性脂肪肝中的作用
批准号:
10751526
负责人:
Jake Brenner Hermanson
金额:
$3.56万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-01 至 2027-06-30
关键词:
16S ribosomal RNA sequencingAffectAlkynesAnimal ModelAutomobile DrivingBifidobacteriumBile AcidsBioinformaticsBiological AssayChemistryCholesterolClinical TrialsColony-forming unitsCommunicationCommunitiesComplexCoupledCritical ThinkingCuesDataDevelopmentDietDietary CholesterolDietary ComponentDiseaseDisease OutcomeDoseDyesElementsEnvironmentExhibitsExtinctionFDA approvedFatty LiverFatty acid glycerol estersFecesFibrosisFlow CytometryFluorescenceFunctional disorderGallbladderGenesGenomicsGerm-FreeGoalsGrowthHealthcareHepaticIn VitroIncidenceIndividualInflammatoryInstitutionIntakeInterventionKnowledgeLibrariesLife StyleLiverLiver CirrhosisLiver DysfunctionLiver FibrosisMassive Parallel SequencingMeasuresMediatingMembraneMetabolicMetabolic DiseasesMetabolic syndromeMetabolismMicrobeMicrobiologyMolecularMusMutagenesisMutationOnset of illnessOpticsOralOrganismOutcomePathogenesisPersonsPopulationPrevalencePrimary carcinoma of the liver cellsPrincipal InvestigatorProliferatingRoleShotgunsSmall IntestinesTechniquesTestingTherapeuticTimeTrainingWritingbeneficial microorganismcandidate identificationcareercostdensitydietarydysbiosisepidemiology studyfeedingfitnessgene functiongerm free conditiongut dysbiosisgut microbesgut microbiomegut microbiotahost-microbe interactionsimprovedin vivoinsightliquid chromatography mass spectrometryliver injuryliver transplantationloss of functionmembermetagenomic sequencingmicrobialmicrobial communitymicrobiomemicrobiome researchmicrobiotamortality riskmutantnon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovel therapeuticspreventprobiotic therapyrRNA Genessaturated fatskillssugaruptakewestern diet

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY The prevalence of Nonalcoholic fatty liver disease (NAFLD) is increasing worldwide, affecting a quarter of the global population. NAFLD may progress to its more severe form, Nonalcoholic steatohepatitis (NASH), which will become the number one indication for liver transplant. While there are over 400 ongoing NAFLD-related clinical trials, there are no FDA-approved therapies. There is an immediate need for strategies to counteract NAFLD/NASH development and progression throughout the world. However, little is known about its pathophysiology. Western diet contributes to disease pathogenesis, mediated in part by the gut microbiome. Epidemiological studies indicate dietary cholesterol closely associates with the incidence of late-stage NAFLD. However, the influences of Western dietary components, such as cholesterol, on gut microbiota are largely unknown. There is a considerable gap in knowledge regarding the mechanistic relationships between discrete Western dietary components, gut microbiota, and the development of NAFLD/NASH. Preliminary studies show Western diets containing high levels of cholesterol induce gut microbial imbalances that precede and are a prerequisite for NAFLD/NASH in Specific pathogen-free (SPF) mice, yet germ-free (GF) mice that lack a gut microbiome are protected from disease. Bifidobacteria are key commensal organisms that are beneficial to the host and are commonly downregulated in metabolic disorders such as NAFLD/NASH. However, environmental cues that drive a loss of Bifidobacteria remain elusive. Preliminary studies show they are lost from the gut upon high-cholesterol feeding in a dose-dependent manner and their relative abundance is negatively correlated with liver damage. These data strongly suggest diet drives a loss of Bifidobacteria which compromises the host and contributes to NAFLD/NASH pathogenesis. It is critical to define the underlying mechanisms if microbiome-based therapeutic strategies against NAFLD/NASH are to be developed. The goal of this proposal is to define the role of dietary cholesterol in driving gut microbial imbalances in NAFLD/NASH pathogenesis. I hypothesize dietary cholesterol drives gut Bifidobacteria elimination which promotes a proinflammatory microbial milieu during the pathogenesis of NAFLD/NASH. To test this hypothesis, I will utilize a combination of in vitro, in vivo, and bioinformatics techniques to 1) Determine critical functional elements that impact Bifidobacteria’s capacity to sustain a niche in the presence of high dietary cholesterol alone vs. within a complex gut microbiota community in NAFLD/NASH development and 2) Elucidate the indirect effect of dietary cholesterol mediated through altered bile acid profile on loss of Bifidobacteria from a complex gut microbiota community in NAFLD/NASH development. By exposing me to central aspects of microbiome research, these studies provide the perfect vehicle for my training and will propel me toward achieving my goal of becoming a Principal Investigator studying interactions between diet, gut microbes, and metabolic disease at a R1 institution.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金